{
  "name" : "moscow.sci-hub.se_5131_eed866f1be2b3c3ab7d5477df4240810_muka2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "The role of Global and Regional DNA Methylation and Histone Modifications in glycemic traits and Type 2 Diabetes: a Systematic Review",
    "authors" : [ "Taulant Muka", "Trudy Voortman", "Symen Ligthart", "Wichor M. Bramer", "Abbas Dehghan" ],
    "emails" : [ "t.muka@erasmusmc.nl" ],
    "sections" : [ {
      "heading" : "Accepted Manuscript",
      "text" : "The role of Global and Regional DNA Methylation and Histone Modifications in glycemic traits and Type 2 Diabetes: a Systematic Review"
    }, {
      "heading" : "Taulant Muka, MD, Jana Nano, MD, Trudy Voortman, PhD, Kim V.E. Braun, RD, MSc, Symen Ligthart, MD, Saverio Stranges, MD, PhD, Wichor M. Bramer, MSc, John Troup, MD, PhD, Rajiv Chowdhury, MD, PhD, Abbas Dehghan, MD, PhD, Oscar",
      "text" : ""
    }, {
      "heading" : "H. Franco, MD, PhD",
      "text" : "PII: S0939-4753(16)30022-9 DOI: 10.1016/j.numecd.2016.04.002 Reference: NUMECD 1583\nTo appear in: Nutrition, Metabolism and Cardiovascular Diseases"
    }, {
      "heading" : "Received Date: 9 December 2015",
      "text" : ""
    }, {
      "heading" : "Revised Date: 4 April 2016",
      "text" : ""
    }, {
      "heading" : "Accepted Date: 4 April 2016",
      "text" : "Please cite this article as: Muka T, Nano J, Voortman T, Braun KVE, Ligthart S, Stranges S, Bramer WM, Troup J, Chowdhury R, Dehghan A, Franco OH, The role of Global and Regional DNA Methylation and Histone Modifications in glycemic traits and Type 2 Diabetes: a Systematic Review, Nutrition, Metabolism and Cardiovascular Diseases (2016), doi: 10.1016/j.numecd.2016.04.002.\nThis is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 1\nThe role of Global and Regional DNA Methylation and Histone Modifications in glycemic 1 traits and Type 2 Diabetes: a Systematic Review. 2\nTaulant Muka, MD1,2*, Jana Nano, MD1*, Trudy Voortman, PhD1,2, Kim V.E. Braun, RD, MSc1, Symen Ligthart, MD 1, Saverio Stranges, MD, PhD3, Wichor M. Bramer, MSc4, John Troup, MD, PhD5, Rajiv Chowdhury, MD, PhD6, Abbas Dehghan, MD, PhD1, Oscar H. Franco, MD, PhD1\n1 Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.\n2 Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Mass, USA. 3 3 Department of Population Health, Luxembourg Institute of Health, Luxemburg. 4 4 Medical Library, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. 5\n5 Research and Development, Metagenics, Inc.\n6 Department of Public Health & Primary Care, Cardiovascular Epidemiology Unit, University 6 of Cambridge, Cambridge, CB1 8RN, United Kingdom. 7 * Authors contributed equally 8\nCorresponding author: Taulant Muka, MD, Department of Epidemiology, Erasmus University 9\nMedical Center, Dr. Molewaterplein 50, Office NA29-14, PO Box 2040, 3000 CA Rotterdam, 10 the Netherlands. Tel: +31 10 7043399. Email: t.muka@erasmusmc.nl 11 12 Word counts: Abstract: 265 words, Text: 3,741 words, Tables: 3, Figures: 2. 13 Running head: epigenetics, type 2 diabetes, glycemic traits. 14\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 2\nABSTRACT 15\nBACKGROUND: New evidence suggests the potential involvement of epigenetic mechanisms 16 in type 2 diabetes (T2D) as a crucial interface between the effects of genetic predisposition and 17 environmental influences. 18 AIM: To systematically review studies investigating the association between epigenetic marks 19 (DNA methylation and histone modifications) with T2D and glycemic traits (glucose and insulin 20 levels, insulin resistance measured by HOMA-IR). 21 METHOD: Six bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, 22 PubMed, Cochrane Central and Google Scholar) were screened until 28th August 2015. We 23 included randomized controlled trials, cohort, case-control and cross-sectional studies in humans 24 that examined the association between epigenetic marks (global, candidate or genome-wide 25 methylation of DNA and histone modifications) with T2D, glucose and insulin levels and insulin 26 metabolism. 27 RESULTS: Of the initially identified 3,879 references, 53 articles, based on 47 unique studies 28 met our inclusion criteria. Overall, data were available on 10,823 participants, with a total of 29 3,358 T2D cases. There was no consistent evidence for an association between global DNA-30 methylation with T2D, glucose, insulin and insulin resistance. The studies reported epigenetic 31 regulation of several candidate genes for diabetes susceptibility in blood cells, muscle, adipose 32 tissue and placenta to be related with T2D without any general overlap between them. Histone 33 modifications in relation to T2D were reported only in 3 observational studies. 34 CONCLUSIONS AND RELEVANCE: Current evidence supports an association between 35 epigenetic marks and T2D. However, overall evidence is limited, highlighting the need for 36\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 3\nfurther larger-scale and prospective investigations to establish whether epigenetic marks may 37 influence the risk of developing T2D. 38 39 KEY WORDS: global DNA methylation, histone modification, type 2 diabetes, glucose, insulin, 40 insulin resistance, epigenetics. 41 42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 4\nINTRODUCITON 56\nType 2 diabetes mellitus (T2D) and its complications constitute a major and growing health 57 problem worldwide, necessitating the delineation of underlying pathogenic mechanisms [1, 2]. A 58 better understanding of factors contributing to development of T2D is essential to improve 59 prevention and treatment strategies [3]. Physical activity, obesity, diet, and aging, account for the 60 most important non-genetic (environmental) risk factors [4, 5]. Ample evidence emphasize the 61 contribution of genetics in the pathophysiology of diabetes as well. Candidate gene and genome-62 wide association studies have identified approximately 153 single-nucleotide polymorphism 63 (SNP) across human genome that explain only a minor fraction of the inter-individual variation 64 in the susceptibility for T2D [6]. However, the causative polymorphisms are still unknown 65 challenging the translation of genetic information into clinical practice [7]. 66\nT2D is the result of a combination of genetic and environmental factors playing a crucial role in 67 etiological processes [8]. Even though both genetic and environmental can be assessed, the 68 informative value in predicting disease or unraveling underlying biological mechanism remains 69 restricted. The role of epigenetic determinants are increasingly being recognized as a potential 70 important link between environmental exposure and disease risk and thus may be a benchmark to 71 capture both their influences [9]. In contrast to genetic modifications, which lead to a change in 72 the base sequence of DNA, epigenetic changes are relatively susceptible to modifications by the 73 environment as well as dysregulation over time. Epigenetics refers to information transmitted 74 during mitosis or meiosis that is very important in gene function. DNA methylation, histone 75 modification, and non-coding RNA are three major types of epigenetic marks [10]. DNA 76 methylation refers to the addition of a methyl group to cytosine at CpG dinucleotides that further 77 influences the function of DNA: activating or repressing the transcriptional activity of a gene. 78\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 5\nPosttranslational histone modifications are another type of epigenetic mark that affect gene 79 expression mainly by altering chromatin structure. Noncoding RNAs have recently emerged as 80 important regulators of gene expression [11]. The genome-wide distribution of these marks and 81 regulators refers as “epigenome” [12]. 82\nFollowing the advent of epigenome investigations, many array-based methods are now opening 83 new windows to further identify epigenetics marks on genome scale related to complex diseases. 84 Currently, Illumina Infinium Methylation450 bead Chip is one of the most widely used platforms 85 praised for its cost-effectiveness, high number of sites and overall good accuracy [13]. Although 86 providing easily reproducible data across studies, deep sequencing technologies are another 87 emerging field that despite drawback of high costs, offer a wider exploration of the genome [14]. 88 Methods investigating site or regions differentially methylated as opposed to genome-wide 89 approaches are continually being used to overcome issues associated with multiple testing 90 corrections. Such example is the bisulfite pyrosequencing, which is based on sequencing-by-91 synthesis methodology and is relatively cost- and time- effective, mostly suitable for DNA 92 methylation analysis of single gene loci [15]. Despite the developments in technology to 93 characterize DNA methylation, the interplay of genes and environment in complex disease such 94 as diabetes is complicated and still remains poorly understood. 95\nThe aim of this paper is to systematically review the current body of evidence on the role of 96 epigenetic marks and T2D and glycemic traits including glucose levels, insulin levels and insulin 97 resistance index (HOMA) specifically focusing on human studies. Studies investigating the 98 association between major types of epigenetics signatures including global DNA methylation, 99\nsite-specific or genome-wide DNA methylation and histone modification with type 2 diabetes 100\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 6\nand glycemic traits are summarized and further discussed. Noncoding RNAs were not addressed 101 in this review. A critical appraisal of current limitations in the field is also presented. 102\nMETHODS 103 Studies identified by search strategy 104 Six bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, PubMed, Cochrane 105 Central and Google Scholar) were searched to identify relevant studies published from 106 conception until 28th August 2015 (described in detail in the method section in the Online 107 Supplemental Material). A total of 3,879 potentially relevant references were retrieved from 108 electronic searches (Figure 1). Based on the title and abstracts, full texts of 65 articles were 109 selected for detailed evaluation. In the full-text assessment, 53 of these articles, based on 47 110 unique studies met our eligibility criteria and were therefore included in this review. 111 RESULTS 112 Characteristics of the included studies 113 Characteristic details of the included studies are summarised in Supplementary Table 1. The 114 majority of studies were performed among Chinese, Swedish and American populations and 115 mostly assessed epigenetic signatures in blood. Overall, 10,823 unique participants were 116 included in the analysis, with a total of 3,358 T2D cases. All available studies, except two that 117 were longitudinal studies, had a cross-sectional or case control design and were judged to be of 118 low or medium quality (methods used to assess the quality of the included studies are described 119 in details in the method section in the Online Supplemental Material). Given the heterogeneous 120 nature of the study characteristics, exposures evaluated and outcomes, we did not perform a 121 quantitative summarization of the studies included in this review. Instead, a narrative synthesis 122\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 7\nand construction of descriptive summary tables was done. A schematic representation of the 123 effect of epigenetic alterations and summary of the results are depicted in Figure 2. 124 Global DNA Methylation, Type 2 Diabetes and Glycemic Traits 125 Global methylation refers to the overall level of methylcytosine in the genome, expressed as 126 percentage of total cytosine. A large portion of methylation sites within the genome are found in 127 repeat sequences and transposable elements, such as Alu and long-interspersed nuclear element 128 (LINE-1) and correlate with total genomic methylation content [16, 17]. Such elements have 129 served as a useful proxy for global DNA methylation as they are commonly heavily methylated 130 in normal tissue and are spread ubiquitously throughout the genome [18, 19]. Other methods 131 (e.g., Luminometric Methylation Assay, LUMA and the [3H]-methyl acceptance 132 based method) that assess global genomic DNA methylation are primarily based on the digestion 133 of genomic DNA by restriction enzymes such as HpaII and MspI [20]. 134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1). Five studies assessed DNA methylation in blood cells whereas the other investigations 137 were performed in skeletal muscle, adipose tissue and pancreatic islets. Six studies reported no 138 association between global DNA-methylation and T2D, whereas one study showed lower levels 139 of global DNA-methylation in T2D cases compared to healthy controls [21] (Table 4). One 140 study reported cell-specific global DNA methylation patterns: in T2D patients, compared to 141 controls, there was an increased degree of global DNA-methylation in B-cells and natural killer 142 cells, but no difference was found overall in peripheral blood (PB) mononuclear cells, 143 lymphocyte cells and monocytes [25]. 144 (ii) Glycemic Traits 145\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 8\nSix studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1). Studies did not report consistent 148 associations between global DNA methylation and glucose levels. Three studies showed 149 increased degree of methylation in LINE-1 elements assessed in blood, skeletal muscle and 150 adipose tissue with increasing levels of plasma glucose [24, 29, 30]. Three studies used other 151 methods to assess global DNA methylation [25, 28] reporting either no association [21] or 152 inverse relationship (Table 1). 153 Insulin metabolism and global DNA methylation was investigated in six studies. Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1). Three studies assessed global DNA-methylation in 156 LINE-1 elements in blood cells and showed no association with insulin (Table 1). Similarly, 157 there was no association with global methylation assessed in adipose abdominal tissue by LUMA 158 method and fasting insulin [28]. However, one study reported an interaction of global DNA-159 methylation with circulating folate concentrations in relation to insulin resistance and showed 160 that a lower degree of methylation and lower plasma folate concentrations were associated with 161 higher insulin resistance (odds ratio = 1.78; 95% Confidence Intervals: 1.02- 3.13) [31]. One 162 study assessed global DNA methylation as a percentage of 2′-deoxycytidine plus 5mdC in 163 genomic DNA and showed a positive association between insulin levels and global DNA-164 methylation assessed in lymphocyte B cells, but no association in natural killer cells [25]. 165 Another study assessed global DNA-methylation in Alu elements and reported a positive 166 association with insulin resistance [32]. 167 Gene Specific DNA Methylation, Type 2 Diabetes and Glycemic Traits 168\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 9\nInvestigating gene-specific DNA methylation is one of the most widely studied approaches in 169 epigenetics because it allows a relatively simple analysis. However, how these epigenetic marks 170 regulate gene expression is not deeply entangled. The association of DNA methylation with gene 171 expression depends on where within the gene sequence the methylation occurs. DNA 172 methylation in the promoter region of the gene down-regulates its expression whereas higher 173 methylation in the gene-body promotes the expression of the gene [33]. Most of the studies 174 included in our review have used a hypotheses-driven and few studies used a candidate gene 175 approach. 176 A. Candidate Gene Studies 177 (i) Type 2 Diabetes 178 There were 25 unique studies that examined methylation sites in or near known candidate genes 179 for diabetes susceptibility (Table 2). Overall, the candidate gene studies showed that T2D cases 180 compared to controls, have higher degree of methylation of IGFNP7, IGFBP1, TLR2, SLC3OA8, 181 GCK, PRCKZ, CTGF and leptin gene in PB cells; PPARGC1A, PDX-1, insulin promoter gene 182 and GLP1R gene in pancreatic islets and APN gene in the adipose tissue. Lower methylation 183 levels were observed for GIPR, CMAK1D, CRY2, CALM2, MCP1, TLR4, FFAR3, PP2AC and 184 CTGF gene in the PB cells; UBASH3A gene in B-cells and PDK4 gene in the skeletal muscle. 185 Five studies found no difference or clear pattern in methylation of the following genes: TCLF7L2 186 and IRS-1 in the PB; GADPH, TFAM and TRIM3 in B-cells; GLP1R in pancreatic islets and 187 PPARGC1A in the skeletal muscle. One study [24] that examined 49 (135 CpG sites) known 188 susceptibility genes for mono- or polygenetic diabetes found 25 CpG sites located in 17 genes to 189 be differentially methylated between diabetes twins and non-diabetes twins (muscle tissue: 190 hypermethylated in T2D - HNF4A, KLF11, DUSP9, HHEX and PPARGC1A; hypomethylated - 191\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 10\nCDKN2A, KCNQ1 and SLC30A8); in subcutaneous adipose tissue: hypermethylated: CIDEC, 192 HNF4A, ADCY5, CDKN2B, IDE, KCNQ1, MTNR1B and TSPAN8; hypomethylated: CAV1, 193 CDKN2A, DUSP9, IRS1 and WFS1. However, only two CpG sites in adipose tissue (CDKN2A 194 and HNF4A) remained significant after adjustment for multiple testing [24]. 195 (ii) Glycemic traits 196 There were eight investigations that examined methylation sites in or near known candidate 197 genes in relation to fasting plasma glucose and glucose 2 hours after the oral glucose tolerance 198 (Table 3). Overall, these studies found higher degree of methylation of L286 gene in the PB and 199 lower levels of methylation of GIPR gene and PPARGC1A gene in the PB and skeletal muscle 200 respectively with increasing levels of plasma glucose. Two studies did not show any association 201 between DNA methylation levels of LEP and ADIPOQ [34] in PB or GLUT4 [28] in abdominal 202 adipose tissue and fasting glucose. Three unique studies [35-38] included pregnant women and 203 found negative correlations between glucose concentrations and methylation levels of ADIPOQ, 204 LPL, IGF1R and IGFBP3 in placenta tissue, and a positive association between plasma glucose 205 and ABCA1 gene methylation in placenta, whereas no association was found for INSR and IGF1. 206 There were 14 studies that examined methylation sites in or near known candidate genes in 207 relation to plasma insulin, insulin expression and insulin resistance (Table 3). These studies 208 found a positive correlation between plasma insulin and methylation at PPARGC1A gene in 209 liver, HTR2A and LY86 genes in blood cells and lower levels of methylation of PPARGC1A gene 210 in skeletal muscle and of insulin promoter gene with increased levels of plasma insulin or mRNA 211 insulin expression. Also, inverse associations were found between insulin resistance and the 212 degree of methylation of TFAM and GIPR3 genes in blood cells and PPARGC1A gene in skeletal 213 muscle. Two studies included pregnant women and reported methylation levels of the maternal 214\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 11\nside of placenta of ADIPOQ negatively correlated with insulin resistance [37] and methylation 215 frequency of IGFBP3 positively correlated with fasting insulin levels and insulin resistance [38]. 216 No association was found between DNA methylation of IGF1R in placenta tissue and fasting 217 insulin or insulin resistance [38]. Collectively, these studies provide evidence that T2D and 218 glycemic traits are associated with altered epigenetic regulation of a number of metabolically 219 important genes. 220 B. Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2). In the pancreatic islets, up to 853 genes (including reported 224 diabetes loci - TCFL72, FTO and KCNQ1) were found to be differentially methylated in diabetes 225 cases compared to healthy controls [39]. In a study of Ribel-Madsen et al., they reported only 226 one CpG site (IL8) in muscle and 7 CpG sites in adipose tissue (ZNF688, HSPA2, C8orf31, 227 SFT2D3, TWIST1, MYOA5) after correction for multiple testing [24]. Epigenome-wide 228 association analysis in whole blood revealed ~69 CpG were reported including loci such as 229 MALT1, ABCG1, PHOPHO1, SOCS3, SREBF1 and TXNIP. 230 As for glycemic traits, two studies performed epigenome-wide analysis [42, 44], but only one 231 significant CpG site (ABCG1) was reported for fasting insulin and insulin resistance after 232 correction (Table 3). 233 Histone Modifications and Type 2 diabetes 234 Three studies examined the association between histone modifications and T2D (Table 4). 235 Patients were reported to have elevated histone H3 acetylation of tumor necrosis alpha and COX-236 2 in the PB mononuclear cells, higher levels of histon H3K9me2 around the IL-1A promoter gene 237\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 12\nand PTEN coding regions and Set7- dependent monomethylation of lysine 4 of histone 3 on 238 promoter gene. 239 DISCUSSION 240 The present work is the first to systematically review the current evidence for the role of 241 epigenetic marks in type 2 diabetes and glycemic traits. The findings of this study indicate no 242 consistent associations between global DNA methylation and diabetes. Conclusive evidence in 243 alterations of histones are still lacking. Although a few diabetes differentially methylated sites 244 have been reported (summarized in Figure 2), the majority of studies have used a candidate-gene 245 approach. No overlap was found between the significant genes differentially methylated on 246 epigenome-wide association studies and studies that used a candidate-gene approach. 247 Global DNA methylation 248 The lack of consistency in the associations of global DNA methylation with both T2D and 249 glycemic traits is not reported only across different methods of measurement, but also across 250 different tissues. However the available information is rather limited and heterogeneous to draw 251 any firm conclusions. The global DNA methylation assessed at long-interspersed nuclear 252 element (LINE-1) was inversely associated with CVD, independent of established cardiovascular 253 risk factors. Conversely, a higher degree of global DNA methylation measured at Alu repeats or 254 by the LUMA method was associated with the presence of CVD [45]. Similarly, no consistent 255 association is observed between global DNA methylation and obesity [46]. Changes in global 256 methylation can affect expression, genomic stability, and chromosomal structure [47]. These 257 contradictory results observed with global DNA methylation may be due to distinct functions 258 between LINE-1 and Alu elements. LINE-1 and Alu repeats represent distinct measures of 259 dispersed DNA methylation, and might have different functions [48]. The quantitative 260\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 13\nassessment of DNA methylation at ALU is about one-third to one-fourth of methylation at LINE-261 1, which may suggest that epigenetic changes at LINE-1 and ALU are measuring different traits 262 [48]. Also, the differences in the reported results may come from the assay used to assess global 263 DNA methylation. For example, global DNA methylation assessed by LUMA modestly 264 correlates with LINE-1 methylation [49]. Additionally, this could be explained by the small 265 sample size and therefore, the lack of power of studies investigating the association between 266 global DNA methylation and T2D until now. 267 Histone modifications 268 This review underscores a gap in the literature concerning T2D and histone modifications. 269 Specific patterns of post-translational modifications to histones act like a molecular “code” 270 recognized and used by non-histone proteins to regulate chromatin functions [50]. These in turn, 271 can be associated with either an active or repressive state of the gene depending on where the 272 modification takes place [51]. Many of the enzymes are involved in the regulation of histones 273 including processes such as acetylation, methylation, phosphorylation, sumoylation and 274 ubiquitination, which may play important roles in the pathogenesis of diabetes [52]. Various 275 families of proteins have been identified to be active in these processes (such as histone 276 deacetylases (HDACs), K-acetyltransferases (KATs), K-methyltransferases (KMTs), and K-277 demethylases (KDMs)) [53]. For instance, a genome-wide association study identified 278 chromosomal region 6q21 associated with both type 1 and type 2 diabetes [54, 55]. Notably, one 279 type of HDAC maps in this region. Further evidence pointing the role of histone modification in 280 T2D can be found in studies conducted using animal models [56, 57]. Taken together, many 281 important enzymes/proteins are involved in histone regulation processes. Further studies are 282 needed to elucidate the role of these mechanism in the pathogenesis of type 2 diabetes. 283\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 14\nEWAS and candidate gene approach 284 Overall, epigenome-wide association studies have provided further insights into the DNA 285 methylation changes associated to T2D. Despite the recognized value of EWAS in uncovering 286 potential novel pathways for common disorders, several limitations are present with regards to 287 the current costs that generally limit the sample size, the varying reproducibility related with 288 different platforms or appropriate analysis approaches [58, 59]. Further attempts to standardized 289 approaches would be a great step in improving the reliability of results and thus the possibility of 290 replicating findings across different studies. Unlike genetic information, which does not very 291 across tissues, methylation is highly variable [58]. Candidate gene approaches, on the other hand, 292 have less stringent multiple testing thresholds on the expense of a more narrow focus on genes. 293 Most studies examining epigenetic changes in T2D and glycemic traits in our systematic review 294 have taken this approach. However, there was an absence of reproducibility of results in the 295 reviewed EWAS. 296 Tissue 297 The ideal tissue to study directly diabetes pathophysiology could be considered to be the 298 pancreatic B-cells. However, collection of this biological material is invasive and not feasible on 299 a large scale. Peripheral blood is the best accessible alternative tissue that reflects multiple 300 metabolic and inflammatory pathways [60, 61]. There is great interest to perform methylation 301 profiling in blood to find methylation disease-related associations since specific methylated 302 regions could be used as potential biomarkers with a great promise of potential clinical utility 303 [62]. Although white blood cell subtype proportions have been previously reported to be 304 associated with T2D [63], methylation changes were not confound by differential cell types as 305 suggested by Yuan et al [40]. However, methylation patterns are thought to be tissue-specific 306\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 15\nthus we might not extrapolate the methylation pattern found in blood to the methylation pattern 307 in other tissues [64]. 308\nBias of the data and Confounding 309\nA number of studies in our review adjusted for age and gender in their analysis, but others are 310 still lacking of these basic covariates. More than 50% of the studies were classified as low 311 quality where most of the part due to lack of proper adjustments. Controlling for different 312 confounders and mediators is important in epigenetic studies since the association is susceptible 313 by temporal factors and spatial effects including age, gender, demographics, ethnicity, 314 environmental, cellular composition, comorbidities and medication use [65-67]. Only a few 315 studies mention adjustment for lifestyle factors such as smoking , alcohol consumption, BMI 316 which might be more prevalent and affecting diabetes patients and have been associated with 317 methylation changes. Comorbidities may also confound epigenetic analysis. Unlike genetic 318 association studies which are less prone to confounding, it is important to incorporate a set of 319 confounding factors in epigenetic analysis. 320\nCausality and study designs 321\nAlthough studies have reported associations between epigenetic markers and diabetes, 322 identifying causal processes is very difficult due to the unstable nature of the epigenome. This is 323 commonly acknowledged in epigenetics epidemiology; unraveling the direction of the 324 association between DNA methylation and the phenotype remains challenging. In human studies, 325 advantages of longitudinal designs could be of help. In all the studies included in this review, 326 except two [41, 68], methylation levels and outcome were measured at the same time point, 327 making it impossible to define whether specific DNA methylation marks are a cause or 328\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 16\nconsequence of the disease. Cohort studies give dynamic information of methylation changes 329 during lifetime and help provide stronger evidence towards causation. The gold standard for 330 establishing causation would be to conduct a longitudinal study with repeated measurements of 331 DNA methylation before disease development and after it. Although this would be costly and 332 logistically challenging, such efforts are on the way. Statistical approaches like Mendelian 333 Randomization where genetic variants are used as proxies for DNA methylation and the outcome 334 of interest can offer an opportunity to study the direction of causation from cross-sectional data 335 [69]. 336\nClinical Implications 337\nEpigenetics might help further identify and understand causes of disease, but is also concerned 338 with risk prediction. Indeed, epigenetics has been shown to be associated with age and moreover, 339 it is a promising biomarker of accumulative environmental exposures [70]. Without being 340 directly involved in the etiology of disease, biomarkers such as epigenetic signatures with high 341 sensitivity and specificity for diabetes would improve the diagnosis, resulting in earlier detection 342 of new cases and introducing new potential therapeutical interventions [41]. Likewise, these 343 epigenetic biomarkers can be used as prognostic tools on diseased individuals. 344\nPerspective and conclusion 345\nPromising results has been reported in the field of diabetes and epigenetics, but still there is long 346 way to go in our understanding of the role of the epigenetics in modifying and regulating human 347 health and disease. Although the field is running on a fast pace, more stringent criteria should be 348 applied to current studies. An increasing tendency to harmonize appropriate methods for DNA 349 methylation detection and reference standards is rapidly evolving and the first steps are made to 350\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 17\nidentify potential DNA methylation biomarkers for type 2 diabetes. Larger sample sizes, 351 replication of results, controlling for a wide range of confounders are paramount. Large-scale 352 longitudinal studies with markers collected over time would undoubtedly contribute to our 353 understanding of the role of epigenetic mechanisms in the evolution of a complex disease. 354 Eventually this may help in predicting an individual’s risk and opens possibilities for introducing 355 targeted strategies to prevent and treat type 2 diabetes. 356\n357\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 18\nContributors: The contributions of the authors were as follows: TM, JN and OHF conceived 358 and designed the study. TM, JN, AB, MC and TV screened title/abstract, obtained full text, 359 determined eligibility of articles and participated in data extraction. JN and TM assessed the 360 quality of the included studies. TM and JN participated in data synthesis/analysis and 361 interpretation of the data. JN, TM, AB, TV, MC, AD and OHF drafted the final manuscript. All 362 authors contributed to the critical revision of the manuscript and approved the final version. 363\nAcknowledgements: TM, TV and KVED reported receiving research support from 364 Metagenics.Inc. JN has been financially supported by Erasmus Mundus Western Balkans 365 (ERAWEB), a project funded by the European Commission. Additional support was provided to 366 AD from the Netherlands Organization for Health Research (NWO) (ZonMW VENI 916.12.154) 367 and the EUR Fellowship. JT worked as scientists at Metagenics Inc. OHF reported receiving 368 grants or research support from Metagenics Inc. These funding sources had no role in design and 369 conduct of the study; collection, management, analysis, and interpretation of the data; and 370 preparation, review or approval of the manuscript. RC, SL and WMB declare no conflict of 371 interest. 372\nFunding/Support: This study was sponsored and funded by Metagenics Inc. 373\nRole of the Funder/Sponsor: Metagenics Inc. with the steering committee were involved in 374 study design; collection, analysis, and interpretation of data; writing of the report; and decision to 375 submit for publication. The funder/sponsor did not have the ability to veto publication of study 376 results. 377\n378\n379\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT 19"
    }, {
      "heading" : "Figure Legend",
      "text" : "Figure 2. Schematic model illustrating how altered epigenetic marks from the influence of environmental and genetic factors may contribute to risk of type 2 diabetes. Altered DNA methylation and expression patterns are specific to tissue.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nTables\nACCEPTED MANUSCRIPT"
    }, {
      "heading" : "LUMA",
      "text" : "M AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\n5mdc, 5 methyl deoxy cytidine; F, female; LINE-1, long interspersed nuclear element 1; LUMA, Luminometric-based assay; M, male; PB, Peripheral blood; PBL, peripheral blood leucocytes; PBMCs, Peripheral blood mononuclear cells; PI, pancreatic islets; SAT, subcutaneous adipose tissue; T2D, type 2 diabetes; WB, whole blood *No difference in global DNA methylation in PBMCs (comprising both lymphocytes and monocytes), or in the lymphocyte or monocyte populations assessed separately was found between T2D cases and non-T2D controls. However, in T2D patients, compared to controls, there was an increased methylation levels in B (p=0.022) and natural killer cells (p=0.004) but not in T helper (p>0.05) and T cytotoxic cells (p>0.05). **Assessed by LUMA method †Significant interaction with circulating folate concentrations were observed and a lower degree of methylation and lower plasma folate concentrations were associated with higher HOMA-IR: OR=1.78, 95%CIs: 1.02-3.13, P=0.041) ‡The study included two study populations, one investigating global methylation in the adipose tissue (n=51) and in the other assessing global methylation in leucocyte (n=509).\nAlu\nPBL M, n=168 Positive association [12] HOMA-IR\nACCEPTED MANUSCRIPT\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nKCNQ1 and SLC30A8 • Hypomethylated genes in subcutanues adipose\ntissue: CAV1, CDKN2A, DUSP9, IRS1 and WFS1.\n• Hypermethylated genes in muscle: HNF4A, KLF11, DUSP9, HHEX and PPARGC1A. Hypomethylated genes in subcutanues adipose tissue: CIDEC, HNF4A, ADCY5, CDKN2B, IDE, KCNQ1, MTNR1B and TSPAN8\nYang B.T. et al. 2012 [18] 9 PI M and F, n=64 PDX-1 gene / 12 CpG and 14 CpG sites for the promoter and enhance region respectively/ Pyrosequencing and Sequenom EpiTyper MassARRAY There was no difference in DNA methylation of CpG sites located in the proximal promoter region close to the PDX-1 transcription start between T2D and non-T2 subjects (1.9 vs. 2.0, P =0.57). 10 of the analyzed CpG sites in the distal promoter region and the enhancer region of PDX-1 showed increased DNA methylation in T2D compared to non-T2D subjects (the absolute increase in the degree of DNA methylation in T2D islets ranged between 6.2 to 18.0% for the analyzed regions, representing fold changes between 1.15 and 1.47). Yang M. et al. 2012 [19] 178 PB Leptin gene/ methylationspecific polymerase chain reaction The methylation rates of leptin gene in T2D group were higher compared to normoglycemic subjects (P < 0.01) Zou L. et al. 2012 [20] 152 PBL M and F, n=272 PRKCZ, 9CpG sites/ bisulfite sequencing\n7 out of 9 CpG sites were hypermethylated in T2D cases compared to non-T2D subjects (P < 0.01 for 6 CpGs and P < 0.05 for one CpG).\nCanivelli S. et al. 2013 [21] 93 PB M and F, n=186\nGIPR gene, 13 CpG sites/ Sequenom EpiTyper MassARRAY\n9 out of 13 CpG sites showed a significant trend toward hypomethylation in T2D patents as compared to controls (P < 0.004). Mean GIPR promoter methylation was lower in T2D patients as compared to controls.\nGillberg L. et al. 2013 [22] 25 Skeletal Muscle\nF, n=124 PPARGC1A gene / bisulfite pyrosequencing\nThere was no difference in DNA methylation between T2D-cases and normal glucose subjects.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nGu H.F. et al. 2013 [23] 100 PB M and F, n=340\nIGFBP7 gene, 3 CpGs/bisulphite sequencing\nDNA methylation levels were significantly increased in newly diagnosed T2D patients compared with non-T2D patients at all the three CPG sites. Combined data from all three CpG sites showed that genomic DNA methylation levels of the IGFBP7 gene in T2D were increased.\nGu T. et al. 2013 [24] 164 PB M, n=402 IGFBP1 gene, 6 CpGs/bisulphite pyrosequencing\nDNA methylation of the 6 CpG sites were significantly higher in T2D patients compared with those in non-T2D subjects ( P < 0.001)\nHall E. et al 2013 [25] 10 PI M and F, n=65 GLP1R gene,12 CpG sites / Sequenom EpiTyper MassARRAY One CpG site showed a small increase in DNA methylation in islets from donors with T2D compared to non-diabetic donors ( P = 0.02, but did not persist after correction for multiple testing). Ma J. et al 2013 [26] 48 PB M and F, n=96 IRS-1 gene, 3 CpG sites/ bisulphite pyrosequencing technology No difference in methylation.\nCanivelli S. et al. 2014 [27] 93 PB M and F, n=186\nTCLF7L2 gene, 22 CpG sites/ Sequenom EpiTyper MassARRAY 14 out of 13 CpG showed significant differences in DNA methylation values between T2D patents as compared to controls ( P < 0.05). After adjustment for multiple testing, only 13 CpGs remained significant.\nCheng J. et al. 2014 [28] 48 PB M and F, n=96 CMAK1D (9 CpGs), CRY2 (5 CpGs) and CALM 2 (4 CpGs) genes, bisulphite sequencing The promoters of the three genes in the PB exhibited low methylation levels for T2D compared to controls ( P < 005).\nRemely M. et al. 2014 [29] 24 WB M and F, n=56 TLR4, TLR2, 4 and 7 CpG sites respectively/ bisulfite pyrosequencing The mean methylation of 4 the CpGs (and of each CpG) in the first exon of TLR4 gene in the obese group were lower compared to T2D subjects whereas no difference in methylation was observed between T2D cases and lean controls ( P =0.95).\nLower methylation levels of seven CpGs (and of each single CpG) in the promoter region of TLR2 were observed in T2D subjects compared to lean subjects but no difference in methylation with obese\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\ncontrols was shown to obese.\nRemely M. et al. 2014 [1] 24 WB M and F, n=56 FFAR3/ bisulfite pyrosequencing\nThere was significant lower methylation in T2D subjects compared to lean mass subjects( P = 0.003)\nSimar D. et al. 2014 [8] 12 B-cells M, n=44 GAPDH, TFAM, TRIM3, UBASH3A genes/bisulphite sequencing\nIn the region tested, only few cytosine residues were found differentially methylated, notably cytosine - 235 relative to the transcription start site of the UBASH3A gene, which was significantly hypomethylated in T2D compared to controls (P < 0.05).\nTang L. et al 2014 [30] 96 PB M and F, n=96 GCK gene/EpiTech Bisulfite Kits\nSignificant elevation of methylation levels of GCK CpG4 were observed in T2D patients than in the healthy controls (P=0.004). This association was specific to males ( P=0.002)\nTang L. et al 2014 [31] 96 PB M and F, n=96 BCL11A gene/EpiTech Bisulfite kit\nNo difference in methylation was observed.\nTros F. et al 2014 [32] 48 WB M and F, n=95 Pp2ac/ bisulfite pyrosequencing\nThe gene was significantly demethylated in T2D patients compared to controls.\nZhang H. et al. 2014 [7] 66 PB M and F, n=104\nCTGF/ bisulfite pyrosequencing\nThe CTGF promoters in individuals in the non-T2D (82.9%) group showed significantly higher methylation levels than those in patients in the diabetes with (31.6%) and without nephropathy (43.2%) (P < 0.05). CTGF promoter methylation level was 72.2 ± 19.3 in the non-T2D group, which was significantly higher than in the T2D without nephropathy (49.2 ± 8.0%, P=0.045) and with nephropathy (22.0 ± 12.9%, P < 0.001).\nJun Z. et al. 2015 [33] 26 Adipose tissue\nM and F, n=124\nAPN promoter/ Denaturing high performance liquid chromatography Methylation positive rate was the lowest in control, middle in obesity and highest in T2D group and the differences were statistically significant (P < 0.05).\nSeman N.A. et al. 2015 [34] 516 PB M and F, n=992\nSLC30A8 gene promoter, 6 CpG sites/ Bisulfite\ntreatment and\nDNA methylation levels at five CpG sites of the gene (except CpG2) in T2D patients were found to be higher than those in NGT subjects, respectively (CpG1 83.9% vs. 81.9%, P = 0.031; CpG3 82.1%\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\npyrosequencing vs. 84.8%, P = 0.003; CpG4 69.6% vs. 66.3%, P = 0.001; CpG5 86.2% vs. 83.7%, P = 0.004; and CpG6 79.8% vs. 78.1%, P = 0.001). Combining all six CpG sites together, total mean values of SLC30A8 DNA methylation levels were significantly increased in T2D patients compared with NGT subjects (82.9%, 95% CI = 79.2% to 80.5% vs. 80.1%, 95% CI = 75.4% to 78.6%, P = 0.014).\nEpigenome wide approaches\nAuthor, Publication year Tissue Discovery sample Validation sample Measurement Correction for multiple tests Main finding Toperoff G. et al. 2012 [35] PB M and F, n= 1169\nNA Affymetrix SNP6 microarray In-deep sequencing: 454 FLX Titanium genome sequencer/ PyroMark Q24 bench-top sequencer Benjamini and Hochberg procedure /q-values\nPool-based genome-scale screen revealed an excess of differentially methylated site in genomic regions previously associated with T2D from genetic studies. Further ultra deep sequencing was performed at selected tip-ranking regions. 13 out of 93 CpG sites showed cace-control differences. A CpG site in the first intron of the FTO gene showed small but significant (P = 0.000021) hypomethylation of cases relative to controls.\nRibel-Madsen R. et al 2012 [2]\nSM and SAT M and F, n=24\nNA HumanMethylati on 27 BeadChip Permutation correction for multiple testing (P adj=0.02)\nOne CpG site in muscle (IL8) and 7 sites in SAT (ZNF668, HSPA2, C8orf31, CD320, SFT2D3, TWIST1, MYO5A) were displaying differentially methylated sites.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nF, female; FDR, false discovery rate; M, male; P, p-value; PB, Peripheral blood; PBL, peripheral blood leucocytes; PBMCs, Peripheral blood mononuclear cells; T2D, type 2 diabetes; PI, pancreatic islets; WB, whole blood; SAT, subcutaneous adipose tissue; * longitudinal study\nVolkmar M.et al 2012 [36] PI M, n=16 NA HumanMethylati on 27 BeadChip 15% group-wise difference of methylation levels was set as a cutoff additional to P Mann– Whitney <0.01\n276 CpG loci affiliated to promotors of 254 genes displaying differential DNA methylation in diabetic islets\nDayeh T. et al. 2014 [37] PI M and F, n=49\nNA HumanMethylati on 450 K BeadChip FDR < 5% 1,649 CpG sites with differential DNA methylation (q<0.05 and difference in DNA methylation ≥5%) in pancreatic islets from 34 non-diabetic versus 15 T2D human donors.\nYuan W. et al. 2014 [38] WB M and F, n= 27 twin pairs\nM and F, n=263\nMeDIP-seq FDR <5% The strongest signal is in the promoter of the MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) gene.\nKulkarni H. et al 2015 [39] WB M and F, n= 850\nNA HumanMethylati on 450 BeadChip FDR <5% 51 CpG sites were significantly associated with T2D.\nChambers J. et al 2015 [40] WB M and F, n= 1074 incident cases\nM and F, n=377 incident cases\nHumanMethylati on 450 K BeadChip P <5 × 10 -7 Methylation markers at five loci (ABCG1,PHOPHO1,SOCS3,SR EBF1,TXNIP) were associated with incident T2D.\nACCEPTED MANUSCRIPT\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nHOMA-IR Lower DNA methylation levels on the maternal side of the placenta were associated with higher insulin resistance index during pregnancy (r =< -0.27, P < 0.05). No association was observed between DNA methylation at the fetal side and HOMA-IR\nCanivelli S. et al. 2013 [21] Fasting glucose PB M and F, n=186\nGIPR gene, 13 CpG sites/ Sequenom EpiTyper MassARRAY\nLower levels of methylation at GIPR promoter gene were associated with higher levels of fasting glucose.\nHOMA-IR Lower levels of methylation at GIPR promoter gene were associated with higher HOMA-IR.\nGillberg L. et al. 2013 [22] Fasting glucose Skeletal Muscle\nF, n=124 PPARGC1A gene, 4CpG sites / bisulfite pyrosequencing. The average PPARGC1A methylation at four CpG sites situated 867-624 bp from the transcription start was borderline negatively correlated with fasting glucose (β=-3.86, 95%CIs=-7.8;0.07), P = 0.05)\nFasting Insulin (and insulin sensitivity)\nHOMA-IR\nThe average PPARGC1A methylation at four CpG sites situated 867-624 bp from the transcription start was borderline negatively correlated with fasting insulin (β=-0.83, 95%CIs=-1.64;-0.02), P = 0.05). Out of the four CpG sites, one site was associated with whole-body insulin sensitivity (b =0.12; P = 0.03). The average PPARGC1A methylation at four CpG sites situated 867-624 bp from the transcription start was borderline negatively correlated with HOMA-IR (β=-1.65, 95%CIs=-3.02;-0.27), P = 0.02)\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nHoude A. et al. 2013 [44] 2-h plasma glucose\nPlacenta tissue and cord blood F, n=100 ABCA1 gene/ bisulfite pyrosequencing\nDNA methylation levels on the maternal side of the placenta were positively correlated with maternal glucose 2h post oral glucose tolerance test ( r=0.25; P =0.02). Cord blood DNA methylation levels were negatively correlated with maternal glucose 2h post oral glucose tolerance test (r =-0.24; P =0.03).\nCanivelli S. et al. 2013 [21]\nFasting Insulin (and insulin sensitivity)\nSkeletal Muscle\nF, n=124 PPARGC1A gene, 4CpG sites / bisulfite pyrosequencing. The average PPARGC1A methylation at four CpG sites situated 867-624 bp from the transcription start was borderline negatively correlated with fasting insulin (β =-0.83, 95%CIs=-1.64;-0.02), P =0.05) .\nOut of the four CpG sites, one site was associated with whole-body insulin sensitivity ( β =0.12; P =0.03).\nWang X. et al. 2014 [30] Fasting Glucose PB M and F, n=703\nLY86 gene, 6 CpG sites/ Bisulphie pyerosequencing\nDNA methylation level of LY86 gene was positively associated with fasting glucose (partial r =0.082, P =0.04)\nFasting Insulin (and insulin sensitivity)\nDNA methylation level of LY86 gene was positively associated with fasting insulin (partial r=0.086, P =0.03) DNA methylation level of LY86 gene was inversely associated with insulin sensitivity (partial r=-0.091, P =0.02)\nHoude A. et al. 2014 [45] 2-h plasma glucose\nPlacenta tissue and cord blood F, n=126 LPL gene/ bisulfite pyrosequencing\nPlacental DNA methylation levels at LPLCpG1 and CpG1 were negatively correlated with maternal glucose\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nDesgagne V. et al. 2014 [46] Impaired glucose tolerance. 2-h plasma glucose and fasting glucose\nPlacenta tissue\nF, n=170 IGF1R (35CpGs), IGFBP3 (6 CpGs), INSR (25 CpGs) and IGF1 (11 CpGs)/ bisulfite pyrosequencing IGF1R-L1 to L5 CpGs and IGFBP3-L1 were found significantly hypomethylated in placentas exposed to IGT (initial sample, n=140) and only IGF1R-L4 was replicated in another set (n=30). No difference was found for the other regions studied.\nIGF1R-L4 (7 CpGs) and IGFBP3-L1 DNA methylation levels were negatively correlated with maternal glucose 2h post oral glucose tolerance test ( IGF1R-L4: r=-0.228; P =0.01; IGFBP3-L1: r=-0.195; P =0.028) and fasting glucose at the second trimester of pregnancy (IGF1R-L4: r=-0.239; P =0.007; IGFBP3-L1: r=-0.152; P =0.089).\nImpaired Fasting insulin and HOMA-IR\nIGFBP3-L1 DNA methylation levels were positively correlated with the third semester fasting insulin (r=0.217, P =0.02) and HOMA-IR (r=0.280; P =0.003). No association was found for IGF1R-L4 and for the second trimester insulin or HOMA-IR.\nKeller M. et al. 2014 [11] Fasting glucose Adipose tissue (SAT and visceral fat)\nM and F, n=51 GLUT4 promoter and the first intron, 22 CpGs/ bisulfite pyrosequencing Methylation levels did not withstand adjustments in their association with glucose homeostasis.\nFasting Insulin No association was found.\nHidalgo B. et al. 2014 [47] Fasting Insulin and HOMA-IR\nPB M and F, n=837\n470,000 CpG sites/ Infinium Human Methylation 450K Bead Chip\nDifferential (hyper) methylation of CpG site within ABCG1 was associated with fasting insulin and HOMA-IR\nPerez-Cornago et al.2014 [48] Insulin WB M and F, n=41 HTR2A gene promotor/ bisulphite sequencing\nHigher levels of HTR2A gene methylation were associated with higher levels of insulin.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\n*Epigenome wide approach β, beta estimates; PB, Peripheral blood; PBL, peripheral blood leucocytes; PBMCs, Peripheral blood mononuclear cells; PI, pancreatic islets; WB, whole blood.\nGarcia-Cardona M.C. et al. 2014 [49]\nFasting Insulin and HOMA-IR\nPB M and F, n=106\nLEP promoter (located at -51 and -31 nt relative to the transcription start site) and ADIPOQ promoter (located at -238 and -74 nt relative to the transcription start site)/ bisulfite pyrosequencing. Methylation frequency of the LEP promoter at both CpGs was negatively associated with HOMA-IR and insulin whereas no association with these traits was observed for ADIPOQ methylation.\nXie X. et al. 2015 [50] Glucose concentrations after a 75gOGTT\nCord blood and placenta F, n=58 PPARGC1A, 6 CpGs sites/ pyrosequencing\nThe maternal gestational glucose level was positively correlated with placental DNA methylation, and negatively correlated with cord blood DNA methylation of the PPARGC1A promoter in a CpG site-specific manner.\nKulkarni H*. et al 2015 [39]\nHOMA-IR PB F (63%) 446 356 CpG sites/ HumanMethylation450 BeadChip\n24 CpG sites were significantly associated with fasting glucose, but not significant after correction for anti-diabetic medication use.\nACCEPTED MANUSCRIPT\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nSupplementary Table 1. Characteristics of the studies included in the systematic review. Lead Author, Publication Date Study Design Location Age ± SD or range (years) Total Participants\nAdjustment No of cases\nQuality\nMiao F. et al 2007 [51] CS USA NA 12 NA 2\nLing C. et al 2008 [13] CCS Sweden NA 19 NA 10 3\nSookioan S. et al. 2010 [41] CS Argentina 50.2 ± 9.9 39 NA NA 5\nGemma C. et al. 2010 [42] CS Argentina 15.3 ± 1.5 122 BMI NA 5\nHou C. et al. 2011 [52] CS China NA 24 NA 3\nOlsson A. et al. 2011[14] CCS Sweden 54-63 64 NA 9 3\nYang B.T. et al. 2011 [15] CCS Sweden 56.7 ± 10.6 57 Disease status, age, sex and BMI\n9 5\nKato S. et al. 2012 [10] CS Japan 59 ± 12 44 NA 26 3\nRibel-Madsen R. et al 2012 [2] CCS Denmark 68.3 ± 7.7 24 NA 12 5\nPearce M.S. et al. 2012 [5] CS UK 49-51 228 Sex NA 8\nZhao J. et al. 2012 [12] CS USA 55.1 ± 2.8 168 Age, smoking, BMI, HDLCholesterol, lowdensity lipoprotein, systolic blood pressure, study affiliation and\nNA 8\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nKulkarni S. et al 2012 [16] CCS Sweden 61 ± 0.5 112 NA 33 5\nLiu Z.H. et al 2012[17] CCS China 51.4 ± 14.1 47 NA 32 4\nToperoff G. et al 2012 [35] CS Israel 40 - 89 1169 Age, lymphocyte percentage\n349 5\nVolkmar M. et al 2012 [36] CCS Italy 42-72.4 16 NA 5 3\nYang B.T. et al.2012 [18] CCS Sweden 56.7 ± 10.6 64 NA 9 2\nZou L. et al. 2012 [20] CCS China 57.4 ± 8.4 272 NA 152 4\nYang M. et al. 2012 [19] CCS China NA 392 NA 178 3\nBouchard L. et al. 2012 [43] CS Canada 28.4 ± 3.6 98 Weight gain between first and third trimester\nNA 7\nLuttmer R. et al. 2013 [9] CS Netherlands 68.7 ± 7.2 738 Age and sex NA 7\nPiyathilake Ch. et al. 2013 [6] CS UK 23 470 Age, race, level of education, minutes of physical activity per week, smoking status, alcohol consumption, parity and use of oral/hormonal contraceptives.\nNA 7\nCanivelli S. et al. 2013 [21] CCS Spain 67.85 ± 10.5 186 NA 93 8\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nGu H.F. et al. 2013 [23] NCCS** Sweden 57-63 340 NA 100 7\nGu T. et al. 2013 [24] CCS Sweden 58 402 BMI 164 7\nHall E. et al 2013 [25] CCS Sweden 45.2-70.4 65 NA 10 4\nMa J. et al 2013[26] CCS China 59 ± 7.5 96 NA 48 7\nHoude A. et al. 2013 [44] CS Canada 28.8 ± 7.4 100 NA NA 7\nGillberg L. et al. 2013 [22] CS Denmark 53.8 ± 10.1 124 NA NA 7\nCanivelli S. et al. 2014 [27] CCS Spain 67.85 ± 10.5 186 Age, sex, physical inactivity, smoking status and waist circumference\n93 8\nCheng J. et al. 2014 [28] CCS China 35-69 96 NA 48 5\nDayeh T. et al. 2014 [37] CCS Sweden 40.5 ± 9.5 49 NA 15 5\nRemely M. et al. 2014 [1] [29] CCS Austria 43.6 ± 9.4 56 NA 24 3\nSimar D. et al. 2014 [8] CCS Denmark 18-60 44 NA 12 5\nTang L. et al 2014 [30, 31] CCS China 50.5- 67.7 96 Age and sex 48 5\nTros F. et al 2014 [32] CCS France 53.8-72.8 95 NA 48 5\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nYuan W. et al.2014 [38] CCS UK NA 290 Disease status, sex, age, BMI, medication use.\n62 7\nZhang H et al. 2014 [7] CCS China 57.4 ± 8.4 104 NA 66 3\nWang X. et al. 2014 [30] CS USA 13-19 703 Age, sex, race and BMI\nNA 8\nHoude A. et al. 2014 [45] CS Canada 28.8 ± 3.9 126 NA NA 6\nDesgagne V. et al. 2014 [46] CCS Canada 29 ± 3.5 170 Maternal age and BMI at first trimester and weight gain between first and third trimester of pregnancy\nNA 8\nGarcia-Cardona M. et al. 2014 [49] CS Mexico 10-16 106 NA NA 6\nPerez-Cornago et al.2014 [48] CS USA 49 ± 1 41 NA NA 5\nHidalgo B. et al. 2014 [47] GW USA 48.3 ± 16.2 837 NA NA 7\nKeller M. et al. 2014 [11] CS Germany 46.44 ± 2.7 51 Age, sex and BMI NA 5\nUlrich C. et al.2015 [4] CS USA 60.6 ± 6.7 173 Age NA 7\nChambers J. et al 2015 [40] NCCS* UK 52.1 ± 10.9 25 372 Age and sex 1074* 8\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT\nBMI, Body mass index; CCS, Case control study; CS, cross-sectional study; NA, not applicable; USA, United States; UK, United Kingdom.\nKulkarni S. et al 2015 [39] CS USA 46.7 ±0.50 850 Age, age square, sex, BMI, diabetic and lipid lowering medication use\n174 7\nPaneni F. et al. 2015 [53] CS Sweden 30-70 68 Age, sex, waist circumference, and fasting glucose\n44 6\nSeman A.N. et al 2015 [34] CCS Malaysia 49.13 ± 12.6 992 NA 516 4\nJun Z. et al. 2015 [33] CCS China 48.5 ± 12.7 124 NA 26 4\nXie X. et al. 2015 [50] CS China 30.6 ± 4.07 58 Gestational weight gain, pregestational BMI, cord blood HOMAIR, newborn birth weight, sex and gestational age ate delivery and maternal age.\nNA 6\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nACCEPTED MANUSCRIPT"
    }, {
      "heading" : "Highlights",
      "text" : "• We identified a total of 53 studies investigating epigenetic regulation, type 2 diabetes and\nglycemic traits, most of which were focused on candidate-gene approaches, as well as nine epigenome-wide association studies.\n• There was no consistent association between global DNA-methylation and type 2\ndiabetes and glycemic traits.\n• Histone modification processes in the mechanism of type 2 diabetes are understudied. • The drawbacks of research in this area include the lack of replication, establishing\ncausality, controlling for potential confounding factors and tissue relevance."
    } ],
    "references" : [ {
      "title" : "The global impact of non-communicable diseases on healthcare spending and national income: a systematic review",
      "author" : [ "T Muka" ],
      "venue" : "Eur J Epidemiol,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2015
    }, {
      "title" : "Comparison of direct costs of type 2 diabetes care: different care models with different outcomes",
      "author" : [ "Giorda", "C.B" ],
      "venue" : "Nutr Metab Cardiovasc Dis,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2014
    }, {
      "title" : "A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative",
      "author" : [ "Shah", "B.R" ],
      "venue" : "Nutr Metab Cardiovasc Dis,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2014
    }, {
      "title" : "Shifts in population dietary patterns and physical inactivity as determinants of global trends in the prevalence of diabetes: An ecological analysis",
      "author" : [ "J.L.C. Oggioni", "J.C.K. Wells", "K. Soroka", "M. Siervo" ],
      "venue" : "Nutrition, Metabolism and Cardiovascular Diseases,",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2014
    }, {
      "title" : "Fruit and vegetable consumption and risk of type 2 diabetes mellitus: A dose-response meta-analysis of prospective cohort studies",
      "author" : [ "D.Z.Y. Wu", "X. Jiang", "W. Jiang" ],
      "venue" : "Nutrition, Metabolism and Cardiovascular Diseases,",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2015
    }, {
      "title" : "Genetics of type 2 diabetes-pitfalls and possibilities",
      "author" : [ "R.B. Prasad", "L. Groop" ],
      "venue" : "Genes (Basel),",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2015
    }, {
      "title" : "Genetic prediction of common diseases. Still no help for the clinical diabetologist! Nutrition Metabolism and Cardiovascular Diseases",
      "author" : [ "S Prudente" ],
      "venue" : null,
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2012
    }, {
      "title" : "Gene-diet interaction in relation to the prevention of obesity and type 2 diabetes: Evidence from the Finnish Diabetes Prevention Study. Nutrition Metabolism and Cardiovascular Diseases",
      "author" : [ "M. Uusitupa" ],
      "venue" : null,
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2005
    }, {
      "title" : "A Six Months Exercise Intervention Influences the Genome-wide DNA Methylation Pattern in Human Adipose Tissue",
      "author" : [ "T Ronn" ],
      "venue" : "Plos Genetics,",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2013
    }, {
      "title" : "An integrated encyclopedia of DNA elements in the human genome",
      "author" : [ "T.E.P. Consortium" ],
      "venue" : "Nature",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2012
    }, {
      "title" : "Milos, RNA sequencing: advances, challenges and opportunities",
      "author" : [ "F. Ozsolak", "P.M" ],
      "venue" : "Nature Reviews Genetics,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2011
    }, {
      "title" : "The NIH Roadmap Epigenomics Mapping Consortium",
      "author" : [ "Bernstein", "B.E" ],
      "venue" : "Nat Biotechnol,",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2010
    }, {
      "title" : "Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome",
      "author" : [ "J Sandoval" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2011
    }, {
      "title" : "Weight Loss after Gastric Bypass Surgery in Human Obesity Remodels Promoter Methylation (vol 3, pg 1020",
      "author" : [ "R Barres" ],
      "venue" : "Cell Reports,",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2013
    }, {
      "title" : "DNA methylation: Bisulphite modification and analysis",
      "author" : [ "Clark", "S.J" ],
      "venue" : "Nature Protocols,",
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2006
    }, {
      "title" : "Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells",
      "author" : [ "M Ehrlich" ],
      "venue" : "Nucleic Acids Res,",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 1982
    }, {
      "title" : "DNA hypomethylation and human diseases",
      "author" : [ "A.S. Wilson", "B.E. Power", "P.L. Molloy" ],
      "venue" : "Biochim Biophys Acta,",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2007
    }, {
      "title" : "A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements",
      "author" : [ "Yang", "A.S" ],
      "venue" : "Nucleic Acids Res,",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2004
    }, {
      "title" : "Analysis of repetitive element DNA methylation by MethyLight",
      "author" : [ "Weisenberger", "D.J" ],
      "venue" : "Nucleic Acids Res,",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2005
    }, {
      "title" : "Using LUMA: a Luminometric-based assay for global DNA-methylation",
      "author" : [ "M. Karimi", "S. Johansson", "T.J. Ekstrom" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2006
    }, {
      "title" : "Metabolic syndrome components are associated with DNA hypomethylation",
      "author" : [ "R Luttmer" ],
      "venue" : "Obes Res Clin Pract,",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2013
    }, {
      "title" : "DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients",
      "author" : [ "S Kato" ],
      "venue" : "Nephron Extra,",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2012
    }, {
      "title" : "Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity",
      "author" : [ "M Remely" ],
      "venue" : "Benefic Microbes,",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2014
    }, {
      "title" : "Genome-Wide Analysis of DNA Methylation Differences in Muscle and Fat from Monozygotic Twins Discordant for Type 2 Diabetes",
      "author" : [ "R Ribel-Madsen" ],
      "venue" : "PLoS ONE,",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2012
    }, {
      "title" : "DNA methylation is altered in B and NK lymphocytes in obese and type 2 diabetic human",
      "author" : [ "D Simar" ],
      "venue" : "Metab Clin Exp,",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2014
    }, {
      "title" : "Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy",
      "author" : [ "H Zhang" ],
      "venue" : "Mol Med Rep,",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2014
    }, {
      "title" : "DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients",
      "author" : [ "M Volkmar" ],
      "venue" : "EMBO J,",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2012
    }, {
      "title" : "Global DNA methylation levels in human adipose tissue are related to fat distribution and glucose homeostasis",
      "author" : [ "M Keller" ],
      "venue" : "Diabetologia,",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2014
    }, {
      "title" : "Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women",
      "author" : [ "Ulrich", "C.M" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2012
    }, {
      "title" : "Global LINE-1 DNA methylation is associated with blood glycaemic and lipid profiles",
      "author" : [ "Pearce", "M.S" ],
      "venue" : "Int J Epidemiol,",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2012
    }, {
      "title" : "A Lower Degree of PBMC L1 Methylation Is Associated with Excess Body Weight and Higher HOMA-IR in the Presence of Lower Concentrations of Plasma Folate",
      "author" : [ "Piyathilake", "C.J" ],
      "venue" : "PLoS ONE,",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2013
    }, {
      "title" : "Global DNA methylation is associated with insulin resistance: A monozygotic twin study",
      "author" : [ "J Zhao" ],
      "venue" : "Diabetes,",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2012
    }, {
      "title" : "Functions of DNA methylation: islands, start sites, gene bodies and beyond",
      "author" : [ "P.A. Jones" ],
      "venue" : "Nat Rev Genet,",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2012
    }, {
      "title" : "DNA methylation of leptin and adiponectin promoters in children is reduced by the combined presence of obesity and insulin resistance",
      "author" : [ "Garcia-Cardona", "M.C" ],
      "venue" : "Int J Obes,",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2014
    }, {
      "title" : "Placental lipoprotein lipase DNA methylation levels are associated with gestational diabetes mellitus and maternal and cord blood lipid profiles",
      "author" : [ "A.A. Houde" ],
      "venue" : "J Dev Orig Health Dis,",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2014
    }, {
      "title" : "Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status",
      "author" : [ "Houde", "A.A" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2013
    }, {
      "title" : "A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance",
      "author" : [ "Manning", "A.K" ],
      "venue" : "Nature Genetics,",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2012
    }, {
      "title" : "Epigenetic dysregulation of the IGF system in placenta of newborns exposed to maternal impaired glucose tolerance",
      "author" : [ "V Desgagne" ],
      "venue" : "Epigenomics,",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2014
    }, {
      "title" : "Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion",
      "author" : [ "T Dayeh" ],
      "venue" : "PLoS Genet,",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2014
    }, {
      "title" : "An integrated epigenomic analysis for type 2 diabetes susceptibility loci in monozygotic twins",
      "author" : [ "W Yuan" ],
      "venue" : "Nat Commun,",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2014
    }, {
      "title" : "Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study",
      "author" : [ "JC L.M. Chambers", "B Lehne" ],
      "venue" : "Lancet Diabetes Endocrinol.,",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2015
    }, {
      "title" : "Novel epigenetic determinants of type 2 diabetes in MexicanAmerican families",
      "author" : [ "H Kulkarni" ],
      "venue" : "Human Molecular Genetics,",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2015
    }, {
      "title" : "Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood",
      "author" : [ "G Toperoff" ],
      "venue" : "Human Molecular Genetics,",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 2012
    }, {
      "title" : "Epigenome-wide association study of fasting measures of glucose, insulin, and homa-ir in the genetics of lipid lowering drugs and diet network study",
      "author" : [ "B Hidalgo" ],
      "venue" : "Diabetes,",
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 2014
    }, {
      "title" : "Epigenetics and human obesity",
      "author" : [ "van Dijk", "S.J" ],
      "venue" : "Int J Obes (Lond),",
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 2015
    }, {
      "title" : "Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals",
      "author" : [ "R. Jaenisch", "A. Bird" ],
      "venue" : "Nature Genetics,",
      "citeRegEx" : "47",
      "shortCiteRegEx" : "47",
      "year" : 2003
    }, {
      "title" : "Global methylation in exposure biology and translational medical science",
      "author" : [ "H.H. Nelson", "C.J. Marsit", "K.T. Kelsey" ],
      "venue" : "Environ Health Perspect,",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2011
    }, {
      "title" : "DNA methylation in white blood cells: association with risk factors in epidemiologic studies",
      "author" : [ "MB Terry", "D.-C.L", "N Vin-Raviv", "HC Wu", "RM. Santella" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "49",
      "shortCiteRegEx" : "49",
      "year" : 2011
    }, {
      "title" : "Defining an epigenetic code",
      "author" : [ "B.M. Turner" ],
      "venue" : "Nature Cell Biology,",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 2007
    }, {
      "title" : "Histone modification patterns and epigenetic codes",
      "author" : [ "A. Lennartsson", "K. Ekwall" ],
      "venue" : "Biochimica Et Biophysica Acta-General Subjects,",
      "citeRegEx" : "51",
      "shortCiteRegEx" : "51",
      "year" : 2009
    }, {
      "title" : "New nomenclature for chromatin-modifying enzymes",
      "author" : [ "Allis", "C.D" ],
      "venue" : "Cell, 2007",
      "citeRegEx" : "53",
      "shortCiteRegEx" : "53",
      "year" : 2007
    }, {
      "title" : "Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24",
      "author" : [ "K W.Y. Xiang", "T Zheng", "W Jia", "J Li", "L Chen" ],
      "venue" : "Diabetes,",
      "citeRegEx" : "54",
      "shortCiteRegEx" : "54",
      "year" : 2004
    }, {
      "title" : "Type 1 diabetes - Evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families",
      "author" : [ "P Concannon" ],
      "venue" : "Diabetes,",
      "citeRegEx" : "55",
      "shortCiteRegEx" : "55",
      "year" : 2005
    }, {
      "title" : "Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta 1-induced renal injury",
      "author" : [ "H Noh" ],
      "venue" : "American Journal of Physiology-Renal Physiology,",
      "citeRegEx" : "56",
      "shortCiteRegEx" : "56",
      "year" : 2009
    }, {
      "title" : "The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1",
      "author" : [ "A L.J. Coste", "M Lagouge", "C Lerin", "MC Antal", "H Meziane" ],
      "venue" : "Proc Natl Acad Sci USA,",
      "citeRegEx" : "57",
      "shortCiteRegEx" : "57",
      "year" : 2008
    }, {
      "title" : "Epigenome-wide association studies for common human diseases",
      "author" : [ "Rakyan", "V.K" ],
      "venue" : "Nature Reviews Genetics,",
      "citeRegEx" : "58",
      "shortCiteRegEx" : "58",
      "year" : 2011
    }, {
      "title" : "Recommendations for the design and analysis of epigenome-wide association studies",
      "author" : [ "Michels", "K.B" ],
      "venue" : "Nature Methods,",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2013
    }, {
      "title" : "Inflammatory Mechanisms in Obesity",
      "author" : [ "M.F. Gregor", "G.S. Hotamisligil" ],
      "venue" : "Annual Review of Immunology,",
      "citeRegEx" : "60",
      "shortCiteRegEx" : "60",
      "year" : 2011
    }, {
      "title" : "The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance",
      "author" : [ "B Vandanmagsar" ],
      "venue" : "Nature Medicine,",
      "citeRegEx" : "61",
      "shortCiteRegEx" : "61",
      "year" : 2011
    }, {
      "title" : "DNA methylation contributes to natural human variation",
      "author" : [ "H Heyn" ],
      "venue" : "Genome Research,",
      "citeRegEx" : "62",
      "shortCiteRegEx" : "62",
      "year" : 2013
    }, {
      "title" : "Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies",
      "author" : [ "E Gkrania-Klotsas" ],
      "venue" : "PLoS ONE,",
      "citeRegEx" : "63",
      "shortCiteRegEx" : "63",
      "year" : 2010
    }, {
      "title" : "DNA methylation landscapes: provocative insights from epigenomics",
      "author" : [ "M.M. Suzuki", "A. Bird" ],
      "venue" : "Nature Reviews Genetics,",
      "citeRegEx" : "64",
      "shortCiteRegEx" : "64",
      "year" : 2008
    }, {
      "title" : "Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood",
      "author" : [ "Zhang", "F.F" ],
      "venue" : "Epigenetics,",
      "citeRegEx" : "65",
      "shortCiteRegEx" : "65",
      "year" : 2011
    }, {
      "title" : "Social Factors and Leukocyte DNA Methylation of Repetitive Sequences: The Multi-Ethnic Study of Atherosclerosis",
      "author" : [ "Subramanyam", "M.A" ],
      "venue" : "PLoS ONE,",
      "citeRegEx" : "66",
      "shortCiteRegEx" : "66",
      "year" : 2013
    }, {
      "title" : "Nutritional influences on epigenetics and age-related disease",
      "author" : [ "F.S. Park LK", "Choi SW" ],
      "venue" : "Proc Nutr Soc. ,",
      "citeRegEx" : "67",
      "shortCiteRegEx" : "67",
      "year" : 2012
    }, {
      "title" : "Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men",
      "author" : [ "T Gu" ],
      "venue" : "Clin Epigenetics,",
      "citeRegEx" : "68",
      "shortCiteRegEx" : "68",
      "year" : 2013
    }, {
      "title" : "Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis",
      "author" : [ "Y Liu" ],
      "venue" : "Nature Biotechnology,",
      "citeRegEx" : "69",
      "shortCiteRegEx" : "69",
      "year" : 2013
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "problem worldwide, necessitating the delineation of underlying pathogenic mechanisms [1, 2].",
      "startOffset" : 85,
      "endOffset" : 91
    }, {
      "referenceID" : 1,
      "context" : "problem worldwide, necessitating the delineation of underlying pathogenic mechanisms [1, 2].",
      "startOffset" : 85,
      "endOffset" : 91
    }, {
      "referenceID" : 2,
      "context" : "prevention and treatment strategies [3].",
      "startOffset" : 36,
      "endOffset" : 39
    }, {
      "referenceID" : 3,
      "context" : "most important non-genetic (environmental) risk factors [4, 5].",
      "startOffset" : 56,
      "endOffset" : 62
    }, {
      "referenceID" : 4,
      "context" : "most important non-genetic (environmental) risk factors [4, 5].",
      "startOffset" : 56,
      "endOffset" : 62
    }, {
      "referenceID" : 5,
      "context" : "Candidate gene and genome62 wide association studies have identified approximately 153 single-nucleotide polymorphism 63 (SNP) across human genome that explain only a minor fraction of the inter-individual variation 64 in the susceptibility for T2D [6].",
      "startOffset" : 249,
      "endOffset" : 252
    }, {
      "referenceID" : 6,
      "context" : "However, the causative polymorphisms are still unknown 65 challenging the translation of genetic information into clinical practice [7].",
      "startOffset" : 132,
      "endOffset" : 135
    }, {
      "referenceID" : 7,
      "context" : "T2D is the result of a combination of genetic and environmental factors playing a crucial role in 67 etiological processes [8].",
      "startOffset" : 123,
      "endOffset" : 126
    }, {
      "referenceID" : 8,
      "context" : "The role of epigenetic determinants are increasingly being recognized as a potential 70 important link between environmental exposure and disease risk and thus may be a benchmark to 71 capture both their influences [9].",
      "startOffset" : 215,
      "endOffset" : 218
    }, {
      "referenceID" : 9,
      "context" : "DNA methylation, histone 75 modification, and non-coding RNA are three major types of epigenetic marks [10].",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 10,
      "context" : "important regulators of gene expression [11].",
      "startOffset" : 40,
      "endOffset" : 44
    }, {
      "referenceID" : 12,
      "context" : "Currently, Illumina Infinium Methylation450 bead Chip is one of the most widely used platforms 85 praised for its cost-effectiveness, high number of sites and overall good accuracy [13].",
      "startOffset" : 181,
      "endOffset" : 185
    }, {
      "referenceID" : 13,
      "context" : "Although 86 providing easily reproducible data across studies, deep sequencing technologies are another 87 emerging field that despite drawback of high costs, offer a wider exploration of the genome [14].",
      "startOffset" : 199,
      "endOffset" : 203
    }, {
      "referenceID" : 14,
      "context" : "Such example is the bisulfite pyrosequencing, which is based on sequencing-by91 synthesis methodology and is relatively cost- and time- effective, mostly suitable for DNA 92 methylation analysis of single gene loci [15].",
      "startOffset" : 215,
      "endOffset" : 219
    }, {
      "referenceID" : 15,
      "context" : "(LINE-1) and correlate with total genomic methylation content [16, 17].",
      "startOffset" : 62,
      "endOffset" : 70
    }, {
      "referenceID" : 16,
      "context" : "(LINE-1) and correlate with total genomic methylation content [16, 17].",
      "startOffset" : 62,
      "endOffset" : 70
    }, {
      "referenceID" : 17,
      "context" : "Such elements have 129 served as a useful proxy for global DNA methylation as they are commonly heavily methylated 130 in normal tissue and are spread ubiquitously throughout the genome [18, 19].",
      "startOffset" : 186,
      "endOffset" : 194
    }, {
      "referenceID" : 18,
      "context" : "Such elements have 129 served as a useful proxy for global DNA methylation as they are commonly heavily methylated 130 in normal tissue and are spread ubiquitously throughout the genome [18, 19].",
      "startOffset" : 186,
      "endOffset" : 194
    }, {
      "referenceID" : 19,
      "context" : ", Luminometric Methylation Assay, LUMA and the [(3)H]-methyl acceptance 132 based method) that assess global genomic DNA methylation are primarily based on the digestion 133 of genomic DNA by restriction enzymes such as HpaII and MspI [20].",
      "startOffset" : 235,
      "endOffset" : 239
    }, {
      "referenceID" : 20,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 21,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 22,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 23,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 24,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 25,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 26,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 27,
      "context" : "134 (i) T2D 135 Eight studies [21-28] examined the association between global DNA methylation and T2D 136 (Table 1).",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 20,
      "context" : "Six studies reported no 138 association between global DNA-methylation and T2D, whereas one study showed lower levels 139 of global DNA-methylation in T2D cases compared to healthy controls [21] (Table 4).",
      "startOffset" : 190,
      "endOffset" : 194
    }, {
      "referenceID" : 24,
      "context" : "One 140 study reported cell-specific global DNA methylation patterns: in T2D patients, compared to 141 controls, there was an increased degree of global DNA-methylation in B-cells and natural killer 142 cells, but no difference was found overall in peripheral blood (PB) mononuclear cells, 143 lymphocyte cells and monocytes [25].",
      "startOffset" : 325,
      "endOffset" : 329
    }, {
      "referenceID" : 20,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 141,
      "endOffset" : 156
    }, {
      "referenceID" : 24,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 141,
      "endOffset" : 156
    }, {
      "referenceID" : 27,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 141,
      "endOffset" : 156
    }, {
      "referenceID" : 28,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 141,
      "endOffset" : 156
    }, {
      "referenceID" : 29,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 141,
      "endOffset" : 156
    }, {
      "referenceID" : 23,
      "context" : "Six studies examined the association between global DNA-methylation and plasma glucose (5 146 studies assessed fasting plasma glucose levels [21, 25, 28-30] and 1 study plasma glucose 2 147 hours after the oral glucose tolerance test [24]) (Table 1).",
      "startOffset" : 234,
      "endOffset" : 238
    }, {
      "referenceID" : 23,
      "context" : "adipose tissue with increasing levels of plasma glucose [24, 29, 30].",
      "startOffset" : 56,
      "endOffset" : 68
    }, {
      "referenceID" : 28,
      "context" : "adipose tissue with increasing levels of plasma glucose [24, 29, 30].",
      "startOffset" : 56,
      "endOffset" : 68
    }, {
      "referenceID" : 29,
      "context" : "adipose tissue with increasing levels of plasma glucose [24, 29, 30].",
      "startOffset" : 56,
      "endOffset" : 68
    }, {
      "referenceID" : 24,
      "context" : "methods to assess global DNA methylation [25, 28] reporting either no association [21] or 152 inverse relationship (Table 1).",
      "startOffset" : 41,
      "endOffset" : 49
    }, {
      "referenceID" : 27,
      "context" : "methods to assess global DNA methylation [25, 28] reporting either no association [21] or 152 inverse relationship (Table 1).",
      "startOffset" : 41,
      "endOffset" : 49
    }, {
      "referenceID" : 20,
      "context" : "methods to assess global DNA methylation [25, 28] reporting either no association [21] or 152 inverse relationship (Table 1).",
      "startOffset" : 82,
      "endOffset" : 86
    }, {
      "referenceID" : 24,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 57,
      "endOffset" : 69
    }, {
      "referenceID" : 27,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 57,
      "endOffset" : 69
    }, {
      "referenceID" : 28,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 57,
      "endOffset" : 69
    }, {
      "referenceID" : 29,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 99,
      "endOffset" : 103
    }, {
      "referenceID" : 30,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 143,
      "endOffset" : 151
    }, {
      "referenceID" : 31,
      "context" : "Three studies 154 examined fasting plasma insulin levels [25, 28, 29], one study insulin secretion [30] and two 155 studies insulin resistance [31, 32] (Table 1).",
      "startOffset" : 143,
      "endOffset" : 151
    }, {
      "referenceID" : 27,
      "context" : "Similarly, 157 there was no association with global methylation assessed in adipose abdominal tissue by LUMA 158 method and fasting insulin [28].",
      "startOffset" : 140,
      "endOffset" : 144
    }, {
      "referenceID" : 24,
      "context" : "One 162 study assessed global DNA methylation as a percentage of 2′-deoxycytidine plus 5mdC in 163 genomic DNA and showed a positive association between insulin levels and global DNA164 methylation assessed in lymphocyte B cells, but no association in natural killer cells [25].",
      "startOffset" : 273,
      "endOffset" : 277
    }, {
      "referenceID" : 31,
      "context" : "165 Another study assessed global DNA-methylation in Alu elements and reported a positive 166 association with insulin resistance [32].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 32,
      "context" : "methylation in the gene-body promotes the expression of the gene [33].",
      "startOffset" : 65,
      "endOffset" : 69
    }, {
      "referenceID" : 23,
      "context" : "One study [24] that examined 49 (135 CpG sites) known 188 susceptibility genes for mono- or polygenetic diabetes found 25 CpG sites located in 17 genes to 189 be differentially methylated between diabetes twins and non-diabetes twins (muscle tissue: 190 hypermethylated in T2D - HNF4A, KLF11, DUSP9, HHEX and PPARGC1A; hypomethylated 191",
      "startOffset" : 10,
      "endOffset" : 14
    }, {
      "referenceID" : 23,
      "context" : "and HNF4A) remained significant after adjustment for multiple testing [24].",
      "startOffset" : 70,
      "endOffset" : 74
    }, {
      "referenceID" : 33,
      "context" : "Two studies did not show any association 201 between DNA methylation levels of LEP and ADIPOQ [34] in PB or GLUT4 [28] in abdominal 202 adipose tissue and fasting glucose.",
      "startOffset" : 94,
      "endOffset" : 98
    }, {
      "referenceID" : 27,
      "context" : "Two studies did not show any association 201 between DNA methylation levels of LEP and ADIPOQ [34] in PB or GLUT4 [28] in abdominal 202 adipose tissue and fasting glucose.",
      "startOffset" : 114,
      "endOffset" : 118
    }, {
      "referenceID" : 34,
      "context" : "Three unique studies [35-38] included pregnant women and 203 found negative correlations between glucose concentrations and methylation levels of ADIPOQ, 204 LPL, IGF1R and IGFBP3 in placenta tissue, and a positive association between plasma glucose 205 and ABCA1 gene methylation in placenta, whereas no association was found for INSR and IGF1.",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 35,
      "context" : "Three unique studies [35-38] included pregnant women and 203 found negative correlations between glucose concentrations and methylation levels of ADIPOQ, 204 LPL, IGF1R and IGFBP3 in placenta tissue, and a positive association between plasma glucose 205 and ABCA1 gene methylation in placenta, whereas no association was found for INSR and IGF1.",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 36,
      "context" : "Three unique studies [35-38] included pregnant women and 203 found negative correlations between glucose concentrations and methylation levels of ADIPOQ, 204 LPL, IGF1R and IGFBP3 in placenta tissue, and a positive association between plasma glucose 205 and ABCA1 gene methylation in placenta, whereas no association was found for INSR and IGF1.",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 37,
      "context" : "Three unique studies [35-38] included pregnant women and 203 found negative correlations between glucose concentrations and methylation levels of ADIPOQ, 204 LPL, IGF1R and IGFBP3 in placenta tissue, and a positive association between plasma glucose 205 and ABCA1 gene methylation in placenta, whereas no association was found for INSR and IGF1.",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 36,
      "context" : "side of placenta of ADIPOQ negatively correlated with insulin resistance [37] and methylation 215 frequency of IGFBP3 positively correlated with fasting insulin levels and insulin resistance [38].",
      "startOffset" : 73,
      "endOffset" : 77
    }, {
      "referenceID" : 37,
      "context" : "side of placenta of ADIPOQ negatively correlated with insulin resistance [37] and methylation 215 frequency of IGFBP3 positively correlated with fasting insulin levels and insulin resistance [38].",
      "startOffset" : 191,
      "endOffset" : 195
    }, {
      "referenceID" : 26,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 168,
      "endOffset" : 176
    }, {
      "referenceID" : 38,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 168,
      "endOffset" : 176
    }, {
      "referenceID" : 23,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 239,
      "endOffset" : 243
    }, {
      "referenceID" : 39,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 280,
      "endOffset" : 287
    }, {
      "referenceID" : 40,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 280,
      "endOffset" : 287
    }, {
      "referenceID" : 41,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 280,
      "endOffset" : 287
    }, {
      "referenceID" : 42,
      "context" : "Epigenome-wide analysis, type 2 diabetes and glycaemic traits 221 Two studies investigated diabetes-associated differentially methylated sites in pancreatic islets 222 [27, 39], one study in skeletal muscle and subcutaneous adipose tissue [24] and four studies in 223 blood cells [40-43] (Table 2).",
      "startOffset" : 280,
      "endOffset" : 287
    }, {
      "referenceID" : 38,
      "context" : "In the pancreatic islets, up to 853 genes (including reported 224 diabetes loci - TCFL72, FTO and KCNQ1) were found to be differentially methylated in diabetes 225 cases compared to healthy controls [39].",
      "startOffset" : 199,
      "endOffset" : 203
    }, {
      "referenceID" : 23,
      "context" : ", they reported only 226 one CpG site (IL8) in muscle and 7 CpG sites in adipose tissue (ZNF688, HSPA2, C8orf31, 227 SFT2D3, TWIST1, MYOA5) after correction for multiple testing [24].",
      "startOffset" : 178,
      "endOffset" : 182
    }, {
      "referenceID" : 41,
      "context" : "230 As for glycemic traits, two studies performed epigenome-wide analysis [42, 44], but only one 231 significant CpG site (ABCG1) was reported for fasting insulin and insulin resistance after 232 correction (Table 3).",
      "startOffset" : 74,
      "endOffset" : 82
    }, {
      "referenceID" : 43,
      "context" : "230 As for glycemic traits, two studies performed epigenome-wide analysis [42, 44], but only one 231 significant CpG site (ABCG1) was reported for fasting insulin and insulin resistance after 232 correction (Table 3).",
      "startOffset" : 74,
      "endOffset" : 82
    }, {
      "referenceID" : 44,
      "context" : "Similarly, no consistent 255 association is observed between global DNA methylation and obesity [46].",
      "startOffset" : 96,
      "endOffset" : 100
    }, {
      "referenceID" : 45,
      "context" : "Changes in global 256 methylation can affect expression, genomic stability, and chromosomal structure [47].",
      "startOffset" : 102,
      "endOffset" : 106
    }, {
      "referenceID" : 46,
      "context" : "LINE-1 and Alu repeats represent distinct measures of 259 dispersed DNA methylation, and might have different functions [48].",
      "startOffset" : 120,
      "endOffset" : 124
    }, {
      "referenceID" : 47,
      "context" : "correlates with LINE-1 methylation [49].",
      "startOffset" : 35,
      "endOffset" : 39
    }, {
      "referenceID" : 48,
      "context" : "269 Specific patterns of post-translational modifications to histones act like a molecular “code” 270 recognized and used by non-histone proteins to regulate chromatin functions [50].",
      "startOffset" : 178,
      "endOffset" : 182
    }, {
      "referenceID" : 49,
      "context" : "These in turn, 271 can be associated with either an active or repressive state of the gene depending on where the 272 modification takes place [51].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 50,
      "context" : "Various 275 families of proteins have been identified to be active in these processes (such as histone 276 deacetylases (HDACs), K-acetyltransferases (KATs), K-methyltransferases (KMTs), and K277 demethylases (KDMs)) [53].",
      "startOffset" : 217,
      "endOffset" : 221
    }, {
      "referenceID" : 51,
      "context" : "For instance, a genome-wide association study identified 278 chromosomal region 6q21 associated with both type 1 and type 2 diabetes [54, 55].",
      "startOffset" : 133,
      "endOffset" : 141
    }, {
      "referenceID" : 52,
      "context" : "For instance, a genome-wide association study identified 278 chromosomal region 6q21 associated with both type 1 and type 2 diabetes [54, 55].",
      "startOffset" : 133,
      "endOffset" : 141
    }, {
      "referenceID" : 53,
      "context" : "Further evidence pointing the role of histone modification in 280 T2D can be found in studies conducted using animal models [56, 57].",
      "startOffset" : 124,
      "endOffset" : 132
    }, {
      "referenceID" : 54,
      "context" : "Further evidence pointing the role of histone modification in 280 T2D can be found in studies conducted using animal models [56, 57].",
      "startOffset" : 124,
      "endOffset" : 132
    }, {
      "referenceID" : 55,
      "context" : "different platforms or appropriate analysis approaches [58, 59].",
      "startOffset" : 55,
      "endOffset" : 63
    }, {
      "referenceID" : 56,
      "context" : "different platforms or appropriate analysis approaches [58, 59].",
      "startOffset" : 55,
      "endOffset" : 63
    }, {
      "referenceID" : 55,
      "context" : "Unlike genetic information, which does not very 291 across tissues, methylation is highly variable [58].",
      "startOffset" : 99,
      "endOffset" : 103
    }, {
      "referenceID" : 57,
      "context" : "Peripheral blood is the best accessible alternative tissue that reflects multiple 300 metabolic and inflammatory pathways [60, 61].",
      "startOffset" : 122,
      "endOffset" : 130
    }, {
      "referenceID" : 58,
      "context" : "Peripheral blood is the best accessible alternative tissue that reflects multiple 300 metabolic and inflammatory pathways [60, 61].",
      "startOffset" : 122,
      "endOffset" : 130
    }, {
      "referenceID" : 59,
      "context" : "There is great interest to perform methylation 301 profiling in blood to find methylation disease-related associations since specific methylated 302 regions could be used as potential biomarkers with a great promise of potential clinical utility 303 [62].",
      "startOffset" : 250,
      "endOffset" : 254
    }, {
      "referenceID" : 60,
      "context" : "Although white blood cell subtype proportions have been previously reported to be 304 associated with T2D [63], methylation changes were not confound by differential cell types as 305 suggested by Yuan et al [40].",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 39,
      "context" : "Although white blood cell subtype proportions have been previously reported to be 304 associated with T2D [63], methylation changes were not confound by differential cell types as 305 suggested by Yuan et al [40].",
      "startOffset" : 208,
      "endOffset" : 212
    }, {
      "referenceID" : 61,
      "context" : "thus we might not extrapolate the methylation pattern found in blood to the methylation pattern 307 in other tissues [64].",
      "startOffset" : 117,
      "endOffset" : 121
    }, {
      "referenceID" : 62,
      "context" : "Controlling for different 312 confounders and mediators is important in epigenetic studies since the association is susceptible 313 by temporal factors and spatial effects including age, gender, demographics, ethnicity, 314 environmental, cellular composition, comorbidities and medication use [65-67].",
      "startOffset" : 294,
      "endOffset" : 301
    }, {
      "referenceID" : 63,
      "context" : "Controlling for different 312 confounders and mediators is important in epigenetic studies since the association is susceptible 313 by temporal factors and spatial effects including age, gender, demographics, ethnicity, 314 environmental, cellular composition, comorbidities and medication use [65-67].",
      "startOffset" : 294,
      "endOffset" : 301
    }, {
      "referenceID" : 64,
      "context" : "Controlling for different 312 confounders and mediators is important in epigenetic studies since the association is susceptible 313 by temporal factors and spatial effects including age, gender, demographics, ethnicity, 314 environmental, cellular composition, comorbidities and medication use [65-67].",
      "startOffset" : 294,
      "endOffset" : 301
    }, {
      "referenceID" : 40,
      "context" : "In all the studies included in this review, 326 except two [41, 68], methylation levels and outcome were measured at the same time point, 327 making it impossible to define whether specific DNA methylation marks are a cause or 328",
      "startOffset" : 59,
      "endOffset" : 67
    }, {
      "referenceID" : 65,
      "context" : "In all the studies included in this review, 326 except two [41, 68], methylation levels and outcome were measured at the same time point, 327 making it impossible to define whether specific DNA methylation marks are a cause or 328",
      "startOffset" : 59,
      "endOffset" : 67
    }, {
      "referenceID" : 66,
      "context" : "of interest can offer an opportunity to study the direction of causation from cross-sectional data 335 [69].",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 40,
      "context" : "Without being 340 directly involved in the etiology of disease, biomarkers such as epigenetic signatures with high 341 sensitivity and specificity for diabetes would improve the diagnosis, resulting in earlier detection 342 of new cases and introducing new potential therapeutical interventions [41].",
      "startOffset" : 295,
      "endOffset" : 299
    } ],
    "year" : 2016,
    "abstractText" : "15 BACKGROUND: New evidence suggests the potential involvement of epigenetic mechanisms 16 in type 2 diabetes (T2D) as a crucial interface between the effects of genetic predisposition and 17 environmental influences. 18 AIM: To systematically review studies investigating the association between epigenetic marks 19 (DNA methylation and histone modifications) with T2D and glycemic traits (glucose and insulin 20 levels, insulin resistance measured by HOMA-IR). 21 METHOD: Six bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, 22 PubMed, Cochrane Central and Google Scholar) were screened until 28 August 2015. We 23 included randomized controlled trials, cohort, case-control and cross-sectional studies in humans 24 that examined the association between epigenetic marks (global, candidate or genome-wide 25 methylation of DNA and histone modifications) with T2D, glucose and insulin levels and insulin 26 metabolism. 27 RESULTS: Of the initially identified 3,879 references, 53 articles, based on 47 unique studies 28 met our inclusion criteria. Overall, data were available on 10,823 participants, with a total of 29 3,358 T2D cases. There was no consistent evidence for an association between global DNA30 methylation with T2D, glucose, insulin and insulin resistance. The studies reported epigenetic 31 regulation of several candidate genes for diabetes susceptibility in blood cells, muscle, adipose 32 tissue and placenta to be related with T2D without any general overlap between them. Histone 33 modifications in relation to T2D were reported only in 3 observational studies. 34 CONCLUSIONS AND RELEVANCE: Current evidence supports an association between 35 epigenetic marks and T2D. However, overall evidence is limited, highlighting the need for 36 M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT",
    "creator" : "Elsevier"
  }
}